JP2024544057A - 血栓塞栓性疾患を予防及び／又は治療する方法 - Google Patents

血栓塞栓性疾患を予防及び／又は治療する方法 Download PDF

Info

Publication number
JP2024544057A
JP2024544057A JP2024532197A JP2024532197A JP2024544057A JP 2024544057 A JP2024544057 A JP 2024544057A JP 2024532197 A JP2024532197 A JP 2024532197A JP 2024532197 A JP2024532197 A JP 2024532197A JP 2024544057 A JP2024544057 A JP 2024544057A
Authority
JP
Japan
Prior art keywords
seq
fxi
variable domain
single variable
immunoglobulin single
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544057A5 (https=
Inventor
霆 徐
群 尹
栄梅 ▲イエン▼
倩 李
燕 王
Original Assignee
蘇州康寧傑瑞生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 蘇州康寧傑瑞生物科技有限公司 filed Critical 蘇州康寧傑瑞生物科技有限公司
Publication of JP2024544057A publication Critical patent/JP2024544057A/ja
Publication of JP2024544057A5 publication Critical patent/JP2024544057A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024532197A 2021-11-30 2022-11-29 血栓塞栓性疾患を予防及び／又は治療する方法 Pending JP2024544057A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111439560 2021-11-30
CN202111439560.3 2021-11-30
PCT/CN2022/134868 WO2023098637A1 (zh) 2021-11-30 2022-11-29 预防和/或治疗血栓栓塞性疾病的方法

Publications (2)

Publication Number Publication Date
JP2024544057A true JP2024544057A (ja) 2024-11-27
JP2024544057A5 JP2024544057A5 (https=) 2025-12-03

Family

ID=86516220

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532197A Pending JP2024544057A (ja) 2021-11-30 2022-11-29 血栓塞栓性疾患を予防及び／又は治療する方法

Country Status (5)

Country Link
US (1) US20250034277A1 (https=)
EP (1) EP4442273A4 (https=)
JP (1) JP2024544057A (https=)
CN (1) CN116199782A (https=)
WO (1) WO2023098637A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025237307A1 (zh) * 2024-05-14 2025-11-20 苏州康宁杰瑞生物科技有限公司 凝血因子FXI/FXIa抑制剂用于治疗肺动脉高压和/或高血压
WO2026032397A1 (en) * 2024-08-09 2026-02-12 Zai Lab (Shanghai) Co., Ltd. Binding molecules with an interleukin-31 receptor subunit alpha-antigen-binding domain and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
CN102558355B (zh) 2011-12-31 2015-02-25 苏州康宁杰瑞生物科技有限公司 基于电荷网络的异二聚体fc改造方法及异二聚体蛋白的制备方法
CN102851338A (zh) 2012-07-25 2013-01-02 苏州康宁杰瑞生物科技有限公司 利用电荷排斥作用制备同二聚体蛋白混合物的方法
RU2757314C2 (ru) * 2016-01-22 2021-10-13 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
IL315266A (en) * 2016-06-14 2024-10-01 Merck Sharp ַ& Dohme Llc Anti-coagulation factor xi antibodies
CN113880949A (zh) * 2020-07-03 2022-01-04 苏州康宁杰瑞生物科技有限公司 凝血因子xi(fxi)结合蛋白
CA3188566A1 (en) * 2020-07-03 2022-01-06 Suzhou Alphamab Co., Ltd. Coagulation factor xi (fxi) binding protein
CN113880951A (zh) * 2020-07-03 2022-01-04 苏州康宁杰瑞生物科技有限公司 凝血因子xi(fxi)结合蛋白
CN113880950A (zh) * 2020-07-03 2022-01-04 苏州康宁杰瑞生物科技有限公司 凝血因子xi(fxi)结合蛋白

Also Published As

Publication number Publication date
WO2023098637A1 (zh) 2023-06-08
CN116199782A (zh) 2023-06-02
US20250034277A1 (en) 2025-01-30
EP4442273A4 (en) 2025-12-24
EP4442273A1 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
JP7500662B2 (ja) 抗第ＸＩ／ＸＩａ因子抗体による処置法
AU2014301041B2 (en) Combination therapy using a Factor XII inhibitor and a C1-Inhibitor
IL240898A (en) Anti-c5a antibodies for manufacture of medicaments for treating complement-associated disorders
RU2704444C2 (ru) Способы лечения ттп иммуноглобулиновыми одиночными вариабельными доменами и их применение
JP2024544057A (ja) 血栓塞栓性疾患を予防及び／又は治療する方法
WO2017133673A1 (zh) 凝血酶抗体、其抗原结合片段及医药用途
CN106687133A (zh) 使用针对cd40l的域抗体治疗自身免疫性疾病的方法
EP2506874A1 (en) Von willebrand factor specific binding agents and uses thereof
WO2021127525A1 (en) Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies
KR20240109269A (ko) 인자 XI/XIa 항체의 투여 요법
CN115803348B (zh) 凝血因子xi(fxi)结合蛋白
CN113880949A (zh) 凝血因子xi(fxi)结合蛋白
CN113880951A (zh) 凝血因子xi(fxi)结合蛋白
TW202405022A (zh) 與抗因子ｘｉ／因子ｘｉａ抗體之組合療法
CN107043423B (zh) 凝血酶抗体、其抗原结合片段及医药用途
CN113880950A (zh) 凝血因子xi(fxi)结合蛋白
AU2024292030A1 (en) Targeted treatment of complement-mediated disease through local complement inhibition based on urinary uc5b-9 detection
HK40084746A (en) Coagulation factor xi (fxi) binding protein
WO2025124481A1 (zh) Tfpi抗体用于治疗血友病
CN120437287A (zh) 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物
EA047046B1 (ru) Антитела к angpt2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251125